None listed
Conditions
Interventions
A placebo inhalation with the DISKUS / ACCUHALER inhaler in the morning and A placebo inhalation with the DISKUS / ACCUHALER inhaler at night.
Group name:fluticasone propionate Type of group
Inhalation of fluticasone propionate at a rate of 100 mcg / dose with the DISKUS / ACCUHALER inhaler in the morning and 1 inhalation of fluticasone propionate at a rate of 100 mcg / dose with the DISKUS / ACCUHALER inhaler at night.
Sponsors
GLAXOSMITHKLINE PERU S.A.,
Eligibility
Inclusion criteria
Inclusion criteria: • Male or female with an age> 12 years • Who are currently receiving b2 short-acting inhaled agonists. • That they are able to comply with the therapy and correctly complete the Daily Registration Cards. • Have a documented history of asthma for a period of at least 6 months.
Exclusion criteria
Exclusion criteria: • That they have received research medication in the study within 4 weeks prior to the first visit or that they are participating concurrently in another clinical trial. • That they are using oral / parenteral corticosteroids or deposit in a period of 12 weeks prior to the first visit. • That they are using inhaled corticosteroids within 12 weeks of the first visit. • That they are using receptor antagonists for leukotrienes within 12 weeks prior to the first visit.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:Symptoms of asthma exacerbation. Measure:Frequency of asthma exacerbations over the weeks. Timepoints:1 - 52 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:Forced expiratory flow forced vital capacity Measure:Forced forced expiratory flow (FEF) between 25% and 75% of forced vital capacity Timepoints:52 week | — |
Countries
Peru, United States
Outcome results
None listed